Search Results

There are 5886 results for: content related to: The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm

  1. You have free access to this content
    Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

    American Journal of Hematology

    Volume 86, Issue 9, September 2011, Pages: 811–819, Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli and Ayalew Tefferi

    Version of Record online : 17 AUG 2011, DOI: 10.1002/ajh.22097

  2. You have free access to this content
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

    American Journal of Hematology

    Volume 91, Issue 2, February 2016, Pages: 252–265, Elias Jabbour and Hagop Kantarjian

    Version of Record online : 22 JAN 2016, DOI: 10.1002/ajh.24275

  3. You have free access to this content
    Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission

    American Journal of Hematology

    Volume 90, Issue 3, March 2015, Pages: 242–249, Harry P. Erba

    Version of Record online : 30 JAN 2015, DOI: 10.1002/ajh.23902

  4. Do we need more drugs for chronic myeloid leukemia?

    Immunological Reviews

    Volume 263, Issue 1, January 2015, Pages: 106–123, Tessa L. Holyoake and G. Vignir Helgason

    Version of Record online : 15 DEC 2014, DOI: 10.1111/imr.12234

  5. You have free access to this content
    Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?

    European Journal of Clinical Investigation

    Volume 40, Issue 10, October 2010, Pages: 918–931, Peter Valent

    Version of Record online : 19 AUG 2010, DOI: 10.1111/j.1365-2362.2010.02328.x

  6. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia

    Immunological Reviews

    Volume 263, Issue 1, January 2015, Pages: 192–209, Maike Buchner, Srividya Swaminathan, Zhengshan Chen and Markus Müschen

    Version of Record online : 15 DEC 2014, DOI: 10.1111/imr.12235

  7. Chronic Myeloid Leukaemia

    Standard Article

    eLS

    Tariq I Mughal and John M Goldman

    Published Online : 15 FEB 2013, DOI: 10.1002/9780470015902.a0002181.pub2

  8. You have full text access to this OnlineOpen article
    Deep molecular responses for treatment-free remission in chronic myeloid leukemia

    Cancer Medicine

    Volume 5, Issue 9, September 2016, Pages: 2398–2411, Stéphanie Dulucq and Francois-Xavier Mahon

    Version of Record online : 1 JUL 2016, DOI: 10.1002/cam4.801

  9. You have free access to this content
    BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation

    American Journal of Hematology

    Volume 87, Issue 3, March 2012, Pages: 298–304, Mary Alikian, Gareth Gerrard, Papagudi G. Subramanian, Katherine Mudge, Pierre Foskett, Jamshid Sorouri Khorashad, Ai Chiin Lim, David Marin, Dragana Milojkovic, Alistair Reid, Katy Rezvani, John Goldman, Jane Apperley and Letizia Foroni

    Version of Record online : 9 JAN 2012, DOI: 10.1002/ajh.22272

  10. You have free access to this content
    Chronic myeloid leukemia: First-line drug of choice

    American Journal of Hematology

    Volume 91, Issue 1, January 2016, Pages: 59–66, Elias Jabbour

    Version of Record online : 23 DEC 2015, DOI: 10.1002/ajh.24249

  11. Treatment-, Patient-, and Disease-Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 8, August 2013, Pages: 868–881, Elizabeth Irvine and Casey Williams

    Version of Record online : 3 APR 2013, DOI: 10.1002/phar.1266

  12. You have free access to this content
    Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

    British Journal of Haematology

    Volume 157, Issue 3, May 2012, Pages: 407–410, Marie-Magdelaine Coude, Odile Luycx, Marie-Estelle Cariou, Odile Maarek, Hervé Dombret, Jean-Michel Cayuela and Delphine Rea

    Version of Record online : 9 JAN 2012, DOI: 10.1111/j.1365-2141.2011.09016.x

  13. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome

    European Journal of Haematology

    Volume 94, Issue 4, April 2015, Pages: 363–367, Tristan Mirault, Delphine Rea, Arshid Azarine and Emmanuel Messas

    Version of Record online : 23 AUG 2014, DOI: 10.1111/ejh.12367

  14. You have free access to this content
    Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase

    Cancer

    Volume 117, Issue 23, 1 December 2011, Pages: 5261–5270, Alfonso Quintás-Cardama, Jorgé E. Cortes and Hagop M. Kantarjian

    Version of Record online : 19 MAY 2011, DOI: 10.1002/cncr.26196

  15. You have free access to this content
    Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

    British Journal of Haematology

    Volume 145, Issue 5, June 2009, Pages: 581–597, Franz Gruber, Satu Mustjoki and Kimmo Porkka

    Version of Record online : 15 APR 2009, DOI: 10.1111/j.1365-2141.2009.07666.x

  16. You have full text access to this OnlineOpen article
    Somatically mutated ABL1 is an actionable and essential NSCLC survival gene

    EMBO Molecular Medicine

    Volume 8, Issue 2, February 2016, Pages: 105–116, Ewelina Testoni, Natalie L Stephenson, Pedro Torres-Ayuso, Anna A Marusiak, Eleanor W Trotter, Andrew Hudson, Cassandra L Hodgkinson, Christopher J Morrow, Caroline Dive and John Brognard

    Version of Record online : 12 JAN 2016, DOI: 10.15252/emmm.201505456

  17. You have free access to this content
    Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

    Cancer

    Volume 121, Issue 6, March 15, 2015, Pages: 863–871, Avichai Shimoni, Yulia Volchek, Maya Koren-Michowitz, Nira Varda-Bloom, Raz Somech, Noga Shem-Tov, Ronit Yerushalmi and Arnon Nagler

    Version of Record online : 11 NOV 2014, DOI: 10.1002/cncr.29141

  18. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation

    European Journal of Haematology

    Volume 94, Issue 3, March 2015, Pages: 270–272, Cristian A. Ferri, Michele Bianchini, Raquel M. Bengió, Elena B. Moiraghi, Mariana S. Gonzalez, María F. Noriega and Irene B. Larripa

    Version of Record online : 13 MAY 2014, DOI: 10.1111/ejh.12358

  19. You have full text access to this OnlineOpen article
    Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 69–81, Tim H. Brümmendorf, Jorge E. Cortes, Cármino Antonio de Souza, Francois Guilhot, Ladan Duvillié, Dmitri Pavlov, Karïn Gogat, Athena M. Countouriotis and Carlo Gambacorti-Passerini

    Version of Record online : 8 SEP 2014, DOI: 10.1111/bjh.13108

  20. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

    Cancer

    Koichi Takahashi, Hagop M. Kantarjian, Yulong Yang, Koji Sasaki, Preetesh Jain, Sara DellaSala, Farhad Ravandi, Tapan Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Elias Jabbour and Jorge E. Cortes

    Version of Record online : 10 AUG 2016, DOI: 10.1002/cncr.30197